Skip to main content
SpringerLink
Log in

Psychotic symptoms in Parkinson’s disease

From description to etiology

  • REVIEW
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

Psychotic symptoms are common in Parkinson’s disease (PD) and occur in at least 20% of medication-treated patients. Benign visual hallucinations usually appear earlier, while malignant hallucinations, confusional states, delusions, paranoid beliefs, agitation, and delirium become more frequent with disease progression. Virtually all antiparkinsonian drugs may produce psychotic symptoms. Cognitive impairment, increased age, disease duration and severity, depression, and sleep disorders have been consistently identified as independent risk factors for their development. Although the precise pathoetiologic mechanisms remain unknown, we review evidence that links ventral dopaminergic pathway dysfunction (overactivity) together with the involvement of other neurotransmitter system imbalances as likely contributors. The clinical importance of the proposed mechanism is that successful management of psychotic symptoms in PD may rely on a multitarget approach to restore neurotransmitter imbalances rather than focusing exclusively on the dopaminergic dysfunction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Aarsland D, Ballard C, Larsen JP, et al. (2001) A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson’s disease with and without dementia. Int J Geriatr Psychiatry 16(5):528–536

    CAS  PubMed  Google Scholar 

  2. Aarsland D, Larsen JP, Cummins JL, et al. (1999) Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol 56(5):595–601

    CAS  PubMed  Google Scholar 

  3. American Psychiatric Association, Diagnostic and Statistical Manual for Psychiatric Disorders (1987) Revised third edition, ed. American Psychiatric Association. Washington, DC

  4. American Psychiatric Association, Diagnostic and statistical manual of mental disorders, 4th edn. 1994, Washington DC

  5. Arnulf I, Bonnet AM, Damier P, et al. (2000) Hallucinations, REM sleep, and Parkinson’s disease: a medical hypothesis. Neurology 55(2):281–288

    CAS  PubMed  Google Scholar 

  6. Baker MG (1999) Depression, psychosis and dementia in Parkinson’s disease. Neurology 52(7 Suppl 3):S1

    CAS  PubMed  Google Scholar 

  7. Ballard CG, Aarsland D, McKeith I, et al. (2002) Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology 59(11):1714–1720

    CAS  PubMed  Google Scholar 

  8. Barclay CL, Hildebrand K, Gray P, et al. (1997) Risk factors for the development of psychosis in Parkinson’s disease. Mov Disord 12(Suppl 1):S108

    Google Scholar 

  9. Barnes J, David AS (2001) Visual hallucinations in Parkinson’s disease: a review and phenomenological survey. J Neurol Neurosurg Psychiatry 70(6):727–733

    CAS  PubMed  Google Scholar 

  10. Bergman J, Lerner V (2002) Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson’s disease. Clin Neuropharmacol 25(2):107–110

    CAS  PubMed  Google Scholar 

  11. Betarbet R, Greenamyre JT (2004) Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of monkeys treated with MPTP. Exp Neurol 189(2):393–403

    CAS  PubMed  Google Scholar 

  12. Birkmayer W, Riederer P (1975) Responsibility of extrastriatal areas for the appearance of psychotic symptoms (clinical and biochemical human postmortem findings). J Neural Transm 37(2):175–182

    CAS  PubMed  Google Scholar 

  13. Brandt J, Spencer M, Folstein MF (1988) The telephone interview for cognitive status. Neuropsychiatry Neuropsychol Behav, pp 111–117

  14. Brink TL, Rose TL, Lum O (1983) Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 17:37–49

    Google Scholar 

  15. Bullock R, Cameron A (2002) Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson’s disease: a case series. Curr Med Res Opin 18(5):258–264

    CAS  PubMed  Google Scholar 

  16. Burn DJ, Troster AI (2004) Neuropsychiatric complications of medical and surgical therapies for Parkinson’s disease. J Geriatr Psychiatry Neurol 17(3):172–180

    PubMed  Google Scholar 

  17. Celesia GG, Barr AN (1970) Psychosis and other psychiatric manifestations of levodopa therapy. Arch Neurol 23(3):193–200

    CAS  PubMed  Google Scholar 

  18. Comella CL, Nardine TM, Diederich NJ, et al. (1998) Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson’s disease. Neurology 51(2):526–529

    CAS  PubMed  Google Scholar 

  19. Comella CL, Tanner CM, Ristanovic RK (1993) Polysomnographic sleep measures in Parkinson’s disease patients with treatment-induced hallucinations. Ann Neurol 34(5):710–714

    CAS  PubMed  Google Scholar 

  20. Cummings JL (1992) Neuropsychiatric complications of drug treatment of Parkinson’s disease in Parkinson’s Disease. In: Huber SJ, Cumming JL (eds) Neurobehavioral Aspects. Oxford University Press: New York, pp 313–327

    Google Scholar 

  21. de Smet Y, Ruberg M, Serdaru M, et al. (1982) Confusion, dementia and anticholinergics in Parkinson’s disease. J Neurol Neurosurg Psychiatry 45(12):1161–1164

    CAS  PubMed  Google Scholar 

  22. Cummings JL (1992) Neuropsychiatric complications of drug treatment of Parkinson’s disease in Parkinson’s Disease. In: Huber SJ, Cumming JL (eds) Neurobehavioral Aspects.Oxford University Press: New York, pp 313–327

    Google Scholar 

  23. Doe De Maindreville A, Fenelon G, Mahieux F (2004) Hallucinations in Parkinson’s disease: A follow-up study. Mov Disord

  24. Dravid AR (1983) Deficits in cholinergic enzymes and muscarinic receptors in the hippocampus and striatum of senescent rats: effect of chronic hydergine treatment. Arch Int Pharmacodyn Ther 264(2):195–202

    CAS  PubMed  Google Scholar 

  25. Fabbrini G, Barbanti P, Aurilia C, et al. (2002) Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease. Neurol Sci 23(1):41–43

    CAS  PubMed  Google Scholar 

  26. Fahn S, Elton RL (1987) Members of the UPDRS development Committee, Unified Parkinson’s disease rating scale, in Recent developments in Parkinson’s disease. Macmillan healthcare information, pp 153–163

  27. Fenelon G, Mahieux F, Huon R, et al. (2000) Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain 123(Pt 4):733–745

    PubMed  Google Scholar 

  28. Fenelon G, Thobois S, Bonnet AM, et al. (2002) Tactile hallucinations in Parkinson’s disease. J Neurol 249(12):1699–1703

    PubMed  Google Scholar 

  29. Fergusson E, Howard R (2000) Donepezil for the treatment of psychosis in dementia with Lewy bodies. Int J Geriatr Psychiatry 15(3):280–281

    CAS  PubMed  Google Scholar 

  30. Fernandez HH, Friedman JH, Jacques C, et al. (1999) Quetiapine for the treatment of drug-induced psychosis in Parkinson’s disease. Mov Disord 14(3):484–487

    CAS  PubMed  Google Scholar 

  31. Fernandez HH, Lannon MC, Friedman JH, et al. (2000) Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson’s disease. Mov Disord 15(3):579–581

    CAS  PubMed  Google Scholar 

  32. Fischer P, Danielczyk W, Simanyi M, et al. (1990) Dopaminergic psychosis in advanced Parkinson’s disease. Adv Neurol 53:391–397

    CAS  PubMed  Google Scholar 

  33. Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189–198

    Article  PubMed  Google Scholar 

  34. Forssman B, Kihlstrand S, Larsson LE (1972) Amantadine therapy in parkinsonism. Acta Neurol Scand 48(1):1–18

    CAS  PubMed  Google Scholar 

  35. Freed CR, Greene PE, Breeze RE, et al. (2001) Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. N Engl J Med 344(10):710–719

    CAS  PubMed  Google Scholar 

  36. Frohna PA, Rothblat DS, Joyce JN, et al. (1995) Alterations in dopamine uptake sites and D1 and D2 receptors in cats symptomatic for and recovered from experimental parkinsonism. Synapse 19(1):46–55

    CAS  PubMed  Google Scholar 

  37. Fuhrer R, Rouillon F (1989) La version franciaise de l’échelle CES-D (Center for Epidemiologic Studies–Depression scale). Description et traduction de l’échelle d’auto-évaluation. Psychiatrie Biol 4:163–166

    Google Scholar 

  38. Gagnon C, Bedard PJ, Di Paolo T (1990) Effect of chronic treatment of MPTP monkeys with dopamine D-1 and/or D-2 receptor agonists. Eur J Pharmacol 178(1):115–120

    CAS  PubMed  Google Scholar 

  39. Giladi N, Treves TA, Paleacu D, et al. (2000) Risk factors for dementia, depression and psychosis in long-standing Parkinson’s disease. J Neural Transm 107(1):59–71

    CAS  PubMed  Google Scholar 

  40. Girotti F, Soliveri P, Carella F, et al. (1988) Dementia and cognitive impairment in Parkinson’s disease. J Neurol Neurosurg Psychiatry 51(12):1498–1502

    CAS  PubMed  Google Scholar 

  41. Gnanalingham KK, Smith LA, Hunter AJ, et al. (1993) Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study. Synapse 14(2):184–194

    CAS  PubMed  Google Scholar 

  42. Goetz CG (1999) Hallucinations in Parkinson’s disease: the clinical syndrome. Adv Neurol 80:419–423

    CAS  PubMed  Google Scholar 

  43. Goetz CG, Burke PF, Leurgans S, et al. (2001) Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study. Arch Neurol 58(2):209–213

    CAS  PubMed  Google Scholar 

  44. Goetz CG, Leurgans S, Pappert EJ, et al. (2001) Prospective longitudinal assessment of hallucinations in Parkinson’s disease. Neurology 57(11):2078–2082

    CAS  PubMed  Google Scholar 

  45. Goetz CG, Pappert EJ, Blasucci LM, et al. (1998) Intravenous levodopa in hallucinating Parkinson’s disease patients: high-dose challenge does not precipitate hallucinations. Neurology 50(2):515–517

    CAS  PubMed  Google Scholar 

  46. Goetz CG, Stebbins GT (1995) Mortality and hallucinations in nursing home patients with advanced Parkinson’s disease. Neurology 45(4):669–671

    CAS  PubMed  Google Scholar 

  47. Goetz CG, Stebbins GT (1993) Risk factors for nursing home placement in advanced Parkinson’s disease. Neurology 43(11):2227–2229

    CAS  PubMed  Google Scholar 

  48. Goetz CG, Tanner CM, Klawans HL (1982) Pharmacology of hallucinations induced by long-term drug therapy. Am J Psychiatry 139(4):494–497

    CAS  PubMed  Google Scholar 

  49. Goetz CG, Vogel C, Tanner CM, et al. (1998) Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology 51(3):811–814

    CAS  PubMed  Google Scholar 

  50. Graham JM, Grunewald RA, Sagar HJ (1997) Hallucinosis in idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 63(4):434–440

    CAS  PubMed  Google Scholar 

  51. Graham WC, Clarke CE, Boyce S, et al. (1990) Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. II.Unilateral intra-carotid infusion of MPTP in the monkey (Macaca fascicularis). Brain Res 514(1):103–110

    CAS  PubMed  Google Scholar 

  52. Greene P, Cote L, Fahn S (1993) Treatment of drug-induced psychosis in Parkinson’s disease with clozapine. Adv Neurol 60:703–706

    CAS  PubMed  Google Scholar 

  53. Haeske-Dewick HC (1995) Hallucinations in Parkinson’s disease: characteristics and associated clinical features. Int J Geriatr Psychiatry 10:487–495

    Google Scholar 

  54. Herzog J, Volkmann J, Krack P, et al. (2003) Two-year follow-up of subthalamic deep brain stimulation in Parkinson’s disease. Mov Disord 18(11):1332–1337

    PubMed  Google Scholar 

  55. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17(5):427–442

    CAS  PubMed  Google Scholar 

  56. Holroyd S, Currie L, Wooten GF (2001) Prospective study of hallucinations and delusions in Parkinson’s disease. J Neurol Neurosurg Psychiatry 70(6):734–738

    CAS  PubMed  Google Scholar 

  57. Hornykiewicz O, Kish SJ (1987) Biochemical pathophysiology of Parkinson’s disease. Adv Neurol 45:19–34

    CAS  PubMed  Google Scholar 

  58. Inzelberg R, Kipervasser S, Korczyn AD (1998) Auditory hallucinations in Parkinson’s disease. J Neurol Neurosurg Psychiatry 64(4):533–535

    CAS  PubMed  Google Scholar 

  59. Inzelberg R, Ramirez A, Nisipeanu P, et al. (2004) Familial risk factors for hallucinations in Parkinson’s disease. Mov Disord 19(Suppl 9):S401

    Google Scholar 

  60. Jellinger K (1987) The pathology of parkinsonism. In: Marsden CD, Fahn S (eds) Movement Disorders, vol 2. Butterworth: London, pp 124–165

  61. Jimenez-Jimenez FJ, Orti-Pareja M, Gasalla T, et al. (1997) Cenesthetic hallucinations in a patient with Parkinson’s disease. J Neurol Neurosurg Psychiatry 63(1):120

    CAS  Google Scholar 

  62. Jurko MF, Andy OJ (1961) Electrical and behavioral changes following thalamotomy. Surg Forum 12:404–406

    CAS  PubMed  Google Scholar 

  63. Korczyn AD, Brooks DJ, Brunt ER, et al. (1998) Ropinirole versus bromocriptine in the treatment of early Parkinson’s disease: a 6-month interim report of a 3-year study. 053 Study Group. Mov Disord 13(1):46–51

    CAS  Google Scholar 

  64. Korczyn AD, Brunt ER, Larsen JP, et al. (1999) A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson’s disease. The 053 Study Group. Neurology 53(2):364–370

    CAS  PubMed  Google Scholar 

  65. Kurita A, Ochiai Y, Kono Y, et al. (2003) The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson’s disease. J Geriatr Psychiatry Neurol 16(3):184–188

    PubMed  Google Scholar 

  66. Lees AJ, Smith E (1983) Cognitive deficits in the early stages of Parkinson’s disease. Brain 106(Pt 2):257–270

    PubMed  Google Scholar 

  67. Lewy FH (1923) Die Lehre vom Tonus und die der Bewegung, ed. S Verlag, Berlin

  68. Lieberman A (1998) Managing the neuropsychiatric symptoms of Parkinson’s disease. Neurology 50(6 Suppl 6): S33–S38; discussion S44–S48

    CAS  PubMed  Google Scholar 

  69. Litvan I, MacIntyre A, Goetz CG, et al. (1998) Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol 55(7):969–978

    CAS  PubMed  Google Scholar 

  70. Mahieux F, Fenelon G, Flahault A, et al. (1998) Neuropsychological prediction of dementia in Parkinson’s disease. J Neurol Neurosurg Psychiatry 64(2):178–183

    CAS  PubMed  Google Scholar 

  71. Makoff AJ, Graham JM, Arranz MJ, et al. (2000) Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson’s disease. Pharmacogenetics 10(1):43–48

    CAS  PubMed  Google Scholar 

  72. McKeith I, Del Ser T, Spano P, et al. (2000) Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 356(9247):2031–2036

    Article  CAS  PubMed  Google Scholar 

  73. McKeith I, Mintzer J, Aarsland D, et al. (2004) Dementia with Lewy bodies. Lancet Neurol 3(1):19–28

    PubMed  Google Scholar 

  74. McKeith IG, Fairbairn AF, Bothwell RA, et al. (1994) An evaluation of the predictive validity and inter-rater reliability of clinical diagnostic criteria for senile dementia of Lewy body type. Neurology 44(5):872–877

    CAS  PubMed  Google Scholar 

  75. McKeith IG, Galasko D, Kosaka K, et al. (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47(5):1113–1124

    CAS  PubMed  Google Scholar 

  76. Melamed E, Zoldan J, Freidberg G (1993) Is hallucinosis in Parkinson’s disease due to central serotonergic hyperactivity? Mov Disord 8:406–407

    Google Scholar 

  77. Merims D, Shabtai H, Korczyn AD, et al. (2004) Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson’s disease. J Neural Transm 111 (10–11):1447–1453

    CAS  PubMed  Google Scholar 

  78. Mojnes H (1949) Paralysis agitans. A clinical and genetic study. Acta Psychiatr Scand, p S54

  79. Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382–389

    CAS  PubMed  Google Scholar 

  80. Morris SK, Olichney JM, Corey-Bloom J (1998) Psychosis in Dementia With Lewy Bodies. Semin Clin Neuropsychiatry 3(1):51–60

    PubMed  Google Scholar 

  81. Moskovitz C, Moses H 3rd, Klawans HL (1978) Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry 135(6):669–675

    CAS  PubMed  Google Scholar 

  82. Naimark D, Jackson E, Rockwell E, et al. (1996) Psychotic symptoms in Parkinson’s disease patients with dementia. J Am Geriatr Soc 44(3):296–299

    CAS  PubMed  Google Scholar 

  83. Nausieda PA, Weiner WJ, Kaplan LR, et al. (1982) Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis. Clin Neuropharmacol 5(2):183–194

    CAS  PubMed  Google Scholar 

  84. Oertel WH (2000) Pergolide versus L-dopa (PELMOPET). Mov Disord 15 (Suppl 3):S4

    Google Scholar 

  85. Olanow CW, Freeman T, Kordower J (2001) Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. N Engl J Med 345(2):146; author reply 147

    CAS  Google Scholar 

  86. Onofrj M, Thomas A, Iacono D, et al. (2001) Switch-over from tolcapone to entacapone in severe Parkinson’s disease patients. Eur Neurol 46(1):11–16

    CAS  Google Scholar 

  87. Papapetropoulos S, Gonzalez J, Lieberman A, et al. (2004) Dementia in Parkinson disease. Prevalence and clinical correlates from a population of brain donors. Mov Disord 19:S192

    Google Scholar 

  88. Pappert EJ, Goetz CG, Niederman FG, et al. (1999) Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson’s disease. Mov Disord 14(1):117–121

    CAS  PubMed  Google Scholar 

  89. Parkes JD, Baxter RC, Marsden CD, et al. (1974) Comparative trial of benzhexol, amantadine, and levodopa in the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry 37(4):422–426

    CAS  PubMed  Google Scholar 

  90. Parkinson Study Group (1997) Entacapone improves motor fluctuations in levodopa-treated Parkinson’s disease patients. Parkinson Study Group. Ann Neurol 42(5):747–755

    PubMed  Google Scholar 

  91. Parkinson Study Group (2000) Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA 284(15):1931–1938

    PubMed  Google Scholar 

  92. Perry EK, Kerwin J, Perry RH, et al. (1990) Cerebral cholinergic activity is related to the incidence of visual hallucinations in senile dementia of the Lewy body type. Dementia 1:2–4

    Google Scholar 

  93. Perry EK, Kerwin J, Perry RH, et al. (1990) Visual hallucinations and the cholinergic system in dementia. J Neurol Neurosurg Psychiatry 53(1):88

    CAS  Google Scholar 

  94. Perry EK, Marshall E, Kerwin J, et al. (1990) Evidence of a monoaminergic-cholinergic imbalance related to visual hallucinations in Lewy body dementia. J Neurochem 55(4):1454–1456

    CAS  PubMed  Google Scholar 

  95. Perry EK, McKeith I, Thompson P, et al. (1991) Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson’s disease, and Alzheimer’s disease. Ann N Y Acad Sci 640:197–202

    CAS  PubMed  Google Scholar 

  96. Piggott MA, Marshall EF, Thomas N, et al. (1999) Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer’s and Parkinson’s diseases: rostrocaudal distribution. Brain 122(Pt 8)1449–1468

    PubMed  Google Scholar 

  97. Poewe W, Hogl B (2000) Parkinson’s disease and sleep. Curr Opin Neurol 13(4):423–426

    CAS  PubMed  Google Scholar 

  98. Poewe WH, Deuschl G, Gordin A, et al. (2002) Efficacy and safety of entacapone in Parkinson’s disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 105(4):245–255

    CAS  PubMed  Google Scholar 

  99. Pope-Coleman A, Tinker JP, Schneider JS (2000) Effects of GM1 ganglioside treatment on pre- and postsynaptic dopaminergic markers in the striatum of parkinsonian monkeys. Synapse 36(2):120–128

    CAS  PubMed  Google Scholar 

  100. Przedborski S, Jackson-Lewis V, Popilskis S, et al. (1991) Unilateral MPTP-induced parkinsonism in monkeys. A quantitative autoradiographic study of dopamine D1 and D2 receptors and re-uptake sites. Neurochirurgie 37(6):377–382

    CAS  PubMed  Google Scholar 

  101. Rabey JM, Treves TA, Neufeld MY, et al. (1995) Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson’s disease. Neurology 45(3 Pt 1):432–434

    CAS  PubMed  Google Scholar 

  102. Raisman R, Cash R, Ruberg M, et al. (1985) Binding of [3H]SCH 23390 to D-1 receptors in the putamen of control and parkinsonian subjects. Eur J Pharmacol 113(3):467–468

    CAS  PubMed  Google Scholar 

  103. Rascol O, Brooks DJ, Korczyn AD, et al. (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342(20):1484–1491

    CAS  PubMed  Google Scholar 

  104. Reading PJ, Luce AK, McKeith IG (2001) Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 16(6):1171–1174

    CAS  PubMed  Google Scholar 

  105. Richard IH, Papka M, Rubio A, et al. (2002) Parkinson’s disease and dementia with Lewy bodies: one disease or two? Mov Disord 17(6):1161–1165

    PubMed  Google Scholar 

  106. Rinne JO, Laihinen A, Rinne UK, et al. (1993) PET study on striatal dopamine D2 receptor changes during the progression of early Parkinson’s disease. Mov Disord 8(2):134–138

    CAS  PubMed  Google Scholar 

  107. Rinne JO, Laihinen A, Ruottinen H, et al. (1995) Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson’s disease: a PET study with [11C]raclopride. J Neurol Sci 132(2):156–161

    CAS  PubMed  Google Scholar 

  108. Rinne JO, Rinne JK, Laakso K, et al. (1985) Dopamine D-1 receptors in the parkinsonian brain. Brain Res 359(1–2):306–310

    CAS  PubMed  Google Scholar 

  109. Rinne UK, Bracco F, Chouza C, et al. (1998) Early treatment of Parkinson’s disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 55(Suppl 1):S23–S30

    Google Scholar 

  110. Rinne UK, Larsen JP, Siden A, et al. (1998) Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 51(5):1309–1314

    CAS  PubMed  Google Scholar 

  111. Rioux L, Frohna PA, Joyce JN, et al. (1997) The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys. Mov Disord 12(2):148–158

    CAS  PubMed  Google Scholar 

  112. Robinson TE, Kolb B (1997) Persistent structural modifications in nucleus accumbens and prefrontal cortex neurons produced by previous experience with amphetamine. J Neurosci 17(21):8491–8497

    CAS  PubMed  Google Scholar 

  113. Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer’s disease. Am J Psychiatry 141(11):1356–1364

    CAS  PubMed  Google Scholar 

  114. Sanchez-Ramos JR, Ortoll R, Paulson GW (1996) Visual hallucinations associated with Parkinson disease. Arch Neurol 53(12):1265–1268

    CAS  PubMed  Google Scholar 

  115. Schenck CH, Bundlie SR, Mahowald MW (1996) Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 46(2):388–393

    CAS  PubMed  Google Scholar 

  116. Schwab RS, Fabing HD, Prichard JS (1950) Psychiatric symptoms and syndromes in Parkinson’s disease. Am J Psychiatry 107:901–907

    Google Scholar 

  117. Singer C, Uzcategui G, Lyons K, et al. (2002) Efficacy and tolerability of amantadine: a retrospective review of old and new indications at a tertiary referral center. Mov Disord 17(S5):279

    Google Scholar 

  118. Steckler T, Sahgal A (1995) The role of serotonergic-cholinergic interactions in the mediation of cognitive behaviour. Behav Brain Res 67(2):165–199

    CAS  PubMed  Google Scholar 

  119. Svensson TH, Mathe JM, Andersson JL, et al. (1995) Mode of action of atypical neuroleptics in relation to the phencyclidine model of schizophrenia: role of 5-HT2 receptor and alpha 1-adrenoceptor antagonism (corrected). J Clin Psychopharmacol 15(1 Suppl 1):S11–S18

    Google Scholar 

  120. Sweet RD, McDowell FH, Feigenson JS, et al. (1976) Mental symptoms in Parkinson’s disease during chronic treatment with levodopa. Neurology 26(4):305–310

    CAS  PubMed  Google Scholar 

  121. Tanner CM, Vogel C, Goetz CG (1983) Hallucinations in Parkinson’s disease: a population study. Ann Neurol 14:136

    Google Scholar 

  122. Wang J, Zhao C, Chen B, et al. (2004) Polymorphisms of dopamine receptor and transporter genes and hallucinations in Parkinson’s disease. Neurosci Lett 355(3):193–196

    CAS  PubMed  Google Scholar 

  123. Wechsler D (1981) Wechsler Adult Intelligence Scale-Revised Manual, ed. P Corporation, Cleveland

  124. Whitehouse PJ, Hedreen JC, White CL 3rd, et al. (1983) Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol 13(3):243–248

    CAS  PubMed  Google Scholar 

  125. Wolters EC (1999) Dopaminomimetic psychosis in Parkinson’s disease patients: diagnosis and treatment. Neurology 52(7 Suppl 3):S10–S13

    CAS  PubMed  Google Scholar 

  126. Wolters EC (2001) Intrinsic and extrinsic psychosis in Parkinson’s disease. J Neurol 248(Suppl 3):S22–S27

    Google Scholar 

  127. Zoldan J, Friedberg G, Goldberg-Stern H, et al. (1993) Ondansetron for hallucinosis in advanced Parkinson’s disease. Lancet 341(8844):562–563

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, University of Miami, School of Medicine, Room 4004, 1501 NW 9th Avenue, 33136, Miami (FL), USA

    Spiridon Papapetropoulos MD, PhD & D. C. Mash PhD

Authors
  1. Spiridon Papapetropoulos MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. C. Mash PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Spiridon Papapetropoulos MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Papapetropoulos, S., Mash, D.C. Psychotic symptoms in Parkinson’s disease. J Neurol 252, 753–764 (2005). https://doi.org/10.1007/s00415-005-0918-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-005-0918-5

Key words

Search

Navigation